Renaissance Technologies’s Recursion Pharmaceuticals RXRX Stock Holding History

Renaissance Technologies’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,400,605	Closed	-$7.37M	–	3561
2026 Q1	$7.37M	Buy	+2,400,605	New	+$9.28M	0.01%	1147
2023 Q3	–	Sell	-350,000	Closed	-$2.62M	–	4041
2023 Q2	$2.62M	Sell	350,000 -65,561	-16%	-$459K	﹤0.01%	1829
2023 Q1	$2.77M	Buy	415,561 +221,661	+114%	+$1.76M	﹤0.01%	1823
2022 Q4	$1.5M	Buy	193,900 +178,700	+1,176%	+$1.75M	﹤0.01%	2266
2022 Q3	$162K	Sell	15,200 -246,400	-94%	-$2.5M	﹤0.01%	3447
2022 Q2	$2.13M	Buy	261,600 +83,200	+47%	+$557K	﹤0.01%	2140
2022 Q1	$1.28M	Buy	+178,400	New	+$1.9M	﹤0.01%	2564

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies's RXRX Position: Q2 2026 in Review

Renaissance Technologies sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 2,400,605 shares — an estimated $7.37M sold.

Renaissance Technologies first reported a position in RXRX in Q1 2022 and held it in 7 quarters. The position peaked at $7.37M in Q1 2026. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Renaissance Technologies reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Renaissance Technologies sold 2,400,605 Recursion Pharmaceuticals shares in Q2 2026, an estimated $7.37M.
Renaissance Technologies first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Renaissance Technologies's Recursion Pharmaceuticals position peaked at $7.37M in Q1 2026.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.